Jasper Therapeutics (NASDAQ: JSPR) — Perfil da empresa, notícias e dados financeiros
Jasper Therapeutics focuses on innovative therapies for bone marrow transplants, improving treatment for severe diseases.
Jasper Therapeutics
Jasper Therapeutics (NASDAQ:JSPR) is a biotechnology company focused on revolutionizing bone marrow and hematopoietic cell transplantations with its cutting-edge technologies and innovative therapies. At the core of their operations, they aim to develop safer, more effective conditioning agents and stem cell engineering processes. Their projects are primarily aimed at treating a wide array of severe and life-threatening diseases, including certain cancers and genetic disorders, by enabling safer, more accessible transplant solutions. Jasper Therapeutics' overarching objective is to enhance patient outcomes and improve the quality of life for those undergoing bone marrow or stem cell transplants.
Resumo
Operações
Produtos e/ou serviços de Jasper Therapeutics
- JSP191, a CD117 monoclonal antibody designed for conditioning patients for hematopoietic cell transplantation.
- Development of a pipeline targeting the stem cell niche for patients with life-threatening hematologic and immune diseases.
- Collaborative projects with academic and pharmaceutical partners to advance stem cell therapy and transplantation.
- Preclinical programs focusing on antibody therapies for improving stem cell engraftment.
- Research and development aimed at creating safer, more effective conditioning regimens that do not rely on high-dose chemotherapy or radiation.
- Services related to the collection, processing, and storage of hematopoietic stem cells for therapeutic use.
equipe executiva do Jasper Therapeutics
- Thomas G. WiggansExecutive Chairman
- Jeetinder Singh MahalPresident, CEO & Director
- Judith Anne ShizuruCo-Founder, Member of Scientific Advisory Board & Director
- Herbert C. CrossCFO & Corporate Secretary
- Matthew E. RosChief Operating Officer
- Alex GrayHead of Investor Relations
- Matthew FordSenior Vice President of Human Resources
- Gregory F. KeenanChief Medical Officer
- Wenru SongExecutive VP and Head of R&D
Principais indicadores financeiros
Resultados divulgados pela Jasper Therapeutics, em USD.
- Cap. de mercado
- 17,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -80,5 mi | -75,8 mi | |
| 0 | -76,2 mi | -71,3 mi | |
| 0 | -68,9 mi | -64,5 mi | |
| 13,5 mi | -51,2 mi | -37,7 mi |